Cite
HARVARD Citation
Reinwald, M. et al. (2014). Efficacy and Pharmacologic Data of Second-Generation Tyrosine Kinase Inhibitor Nilotinib in BCR-ABL-Positive Leukemia Patients with Central Nervous System Relapse after Allogeneic Stem Cell Transplantation. BioMed research international. p. . [Online].